Event-Related Potentials in Parkinson’s Disease Patients with Visual Hallucination

Table 1

Characteristics in PD-H, PD-NH, and controls.

	PD-H	PD-NH	Controls	p
	Age^1, years	67.79 ± 7.93	66.36 ± 9.68		68.29 ± 6.83	0.753
Women^1, n (%)	5 (36)	7 (28)	10 (59)	0.107
Education^1, y	9.27 ± 6.65	10.88 ± 4.16	12.16 ± 3.32	0.245
Disease duration^2, y	11.73 ± 6.41	6.20 ± 4.86	n/a	0.007
Duration of levodopa^2, y	8.44 ± 5.78	3.04 ± 3.57	n/a	0.004
H&Y^2	2.65 ± 0.89	1.52 ± 0.65	n/a	<0.001
MMSE^1 (score)	27.73 ± 2.20	27.58 ± 1.36	28.41 ± 1.37	0.472
HDI^1 (score)	5.00 ± 4.67		0.25 ± 0.79	<0.001
UPDRS-III motor^2 (score)	27.92 ± 13.00	14.20 ± 8.42	n/a	<0.001
Levodopa-equivalent dose	863.8 ± 390.6	311.2 ± 160.5	n/a	0.08

PD-H: PD patients with visual hallucinations; PD-NH: PD patients without visual hallucinations; H&Y: Hoehn and Yahr stage; HDI: Hamilton depression index; UPDRS: Unified Parkinson’s Disease Rating Scale; n/a: not available.
p: p value, ; by ¹ANOVA ²t-test.